Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

The novel Bruton tyrosine kinase inhibitor ibrutinib and phosphatidyl-4-5-biphosphate 3-kinase-δ inhibitor idelalisib are promising drugs for the treatment of chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma, either alone or in combination with anti-CD20 antibodies. We investigated the p...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica
Main Authors: Roit, Fabio Da, Engelberts, Patrick J., Taylor, Ronald P., Breij, Esther C.W., Gritti, Giuseppe, Rambaldi, Alessandro, Introna, Martino, Parren, Paul W.H.I., Beurskens, Frank J., Golay, Josée
Format: Artigo
Language:Inglês
Published: Ferrata Storti Foundation 2015
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4281316/
https://ncbi.nlm.nih.gov/pubmed/25344523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.107011
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items